Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bio-three

ApprovedSmall molecule

KKaohsiung Veterans General Hospital.

Bio-three is one of 8 small molecule programs targeting Enteritis. It is currently in Approved.

1

Indications

1

Total Trials

0

Active Trials

7

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnteritisActive, not recruiting

EnteritisApproved

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Enteritis

#DrugCompanyPhaseTrials

Qvar

SSchering-Plough

Entyvio

Bio-three

KKaohsiung Veterans General Hospital.

Emapalumab

SSwedish Orphan Biovitrum

Tetrahydrobiopterin

OOrphanetics Pharma Entwicklungs GmbH

OPS-2071

Glutamine

UCB-Mncs

ZZhejiang Cancer Hospital

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enteritis1 trial

The Treatment Effect of Bio-Three on Children With Enteritis

Completed·KKaohsiung Veterans General Hospital.·Phase 4·NCT01480947·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bio-three. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bio-three compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bio-three. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kaohsiung Veterans General Hospital. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: KKaohsiung Veterans General Hospital.

Related News